Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

iRhythm Technologies, Inc. (IRTC)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
152.50-3.28 (-2.11%)
At close: 04:00PM EDT
152.50 0.00 (0.00%)
After hours: 04:11PM EDT
Advertisement

Yahoo Finance will soon be upgrading our Conversations message board platform to provide a better experience for our users. Only comments published since April 21, 2021 will be visible on Yahoo Finance after the upgrade. If you wish to download and save any of your older comments, please submit a request via the Privacy Dashboard by no later than Aug. 15, 2022.

Sign in to post a message.
  • J
    Jessica
    Are you guys part of (http://traderspot.club)? They just talked about IRTC
  • B
    BigDickBlack
    biz model
  • E
    Emily
    IRTC looks like trash today - I bet it falls from here. Glad I am signed up to (http://Achieverspot.tech) so that I can get stocks that actually move!
  • W
    Winorlose
    High employee costs will kill profits! Never buy pump
  • B
    Benjo
    I am for $250 !!
    Bullish
  • D
    DANI
    Up $ 27 on just "comments".... has no material value.... put killer manipulation
  • R
    Robert
    Nice 20% jump for them completely guessing a CMS rate for next year. I guess the bag holders are desperate to recoup some of the millions in losses...
  • 3
    30 Trillion Debt
    Over 100% growth the last year for what? something weird about this stock how u lose so much money in a bear market and rise that much? weird
  • B
    Benjo
    Buying to 200+
    Bullish
  • R
    Robert
    Amazing how much Insider selling for such a money losing company...
  • n
    nomdeguerre
    Looks like my post from yesterday was censored.

    Down again today after yesterday's crash. 8.75% was an institution selling. Their business model is broken. They weren't making money with a good reimbursement code, much less the revised one. And there's zero room for international growth as the reimbursement isn't even as generous as Novitas. Again, I wouldn't short the stock as someone might finally catch on to what the future of the industry is and make some smart acquisitions, but I haven't seen any sign of it from anyone in charge over there.
  • J
    Jamie
    How does a company that has no profit and has more competitors coming into their market taking market share have a valuation of over $4B?
    The call yesterday with the CEO and CFO gave no indication that their revenue would increase substantially.
    It was said that 5% would be high for just that portion of their billing and business.
    Do these analysts who increase their stock valuation significantly the morning after a stock spike get paid by the company or hold shares themselves?
    There will be an earnings call tomorrow where they will announce further loss and negative earning/share and this stock has gone up almost 50% in a day and a half.
    Will this company every be profitable ?
    And yes, I am short only because I can’t understand the reason for such a drastic jump in the stock and valuation over getting their own billing codes, rather than the temporary ones they were using. Even with those codes they are projecting only a very small potential increase in revenue which is low single digits from what they have said on their call.
    Very confusing
  • j
    jeff
    Does anyone ever read comments on this stock or care about what it is worth? I am trying to understand why anyone would own or buy this stock. It has no competitive advantage and at lease five other companies sell a comparable or better patch. The insurance reimbursement is expected to go down 40% or more next year and they have never made a profit with it this high now. They just diluted shareholder equity with over 1.5 million more shares. This has got to be the most over valued stock on the market. What possible reason does anybody have to own or buy it?
    Bearish
  • D
    Dave
    Oppenheimer analyst Suraj Kalia said IRTC's business business mode is "in jeopardy" and the company's gross margin for FY21 is at risk by at least about 1000 basis points. Kalia made the comments in a note before an 8:30am conference call that IRTC hosted.
  • S
    Seyed
    The firm has just placed a news release which indicates "The Company believes that the published rates by Novitas on January 29, 2021, are crosswalked from CPT codes 93224 and 93226, which are existing CPT codes for external continuous electrocardiographic recording up to 48 hours."
    Bullish
  • G
    George
    The stock is overpriced. compare with BioTelemetry, Inc.: Same business for cardiac monitoring, revenue 211M, P/E ratio 16.58, Market cap 800M. iRhythm Technologies, Inc: Revenue 80.78M, profit negative, Market cap 1.18B?
  • s
    spirit of 76
    Never seen a company (other than Amazon) lose so much $$$ and the stock keeps going Up?? Their day of reckoning coming.
  • w
    wererabbit
    What's amazing is this news came out basically two months ago and so many people ignored, it was the probably best stock out there the short. This definitive ruling means that these guys are losing what, 2/3 of their revenue?
    Neutral
  • j
    jeff
    I am an independent medical device sales rep. I recently added a product in the remote heart monitoring market that competes with the Zio patch. I visit cardiologists every day and ask them what type of heart monitor they use. Their responses generally are that they use the Bardis CAM patch (which beat ZIO in a head to head study recently) , the G-Med patch, the Bio-tel patch or the Cardiac Insight patch. All these patches allow the practice to download the data directly from the patch monitor to their computer and get the results back in 24 hours versus Zio which requires them to physically send it in a package and wait up to 5 days or more for the results. Many of them had used ZIO in the past when they were the first to market, but not now. I wonder where their current revenue is coming from since thy seem to have no competitive advantage. I represent a non public holter monitor that allows recordeing for up to 30 days versus the 14 day maximum of Zio and is non-adhesive so it is easier to put on and take off. I also am acutely aware of the potential reimburse cut when the temporary "T" code is reviewed next year as laid out in the very incisive report by a investment strategist that has shorted the stock. My advice is to just do your own due diligence and ask some cardiologists if they are using Zio and what they think of their competitors.
Advertisement
Advertisement